Date: 2012-02-05
Type of information:
phase: 2
Announcement: initiation
Company: GSK (UK) Galapagos (Belgium)
Product: GSK2586184 (formerly GLPG0778)
Action
mechanism: GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos\' osteoarthritis alliance with GSK.
Disease: systemic lupus erythematosus
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: Galapagos has announced that GSK plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE). GSK2586184 is the second selective JAK1 molecule discovered by Galapagos to enter Phase 2 studies. GSK plans to initiate a 12 week, multi-center, dose-ranging, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients.
GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK €34M in additional milestones plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.
